BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32718987)

  • 1. Checkpoint inhibitor-related renal vasculitis and use of rituximab.
    Mamlouk O; Lin JS; Abdelrahim M; Tchakarov AS; Glass WF; Selamet U; Buni M; Abdel-Wahab N; Abudayyeh A
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
    Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
    BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange.
    Sagmeister MS; Weiss M; Eichhorn P; Habicht A; Habersetzer R; Fischereder M; Schönermarck U
    BMC Nephrol; 2018 Oct; 19(1):270. PubMed ID: 30340563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ANCA-associated vasculitis in scleroderma: A renal perspective
.
    Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
    Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment of ANCA-associated vasculitis.
    Raffray L; Guillevin L
    Expert Opin Biol Ther; 2020 Aug; 20(8):899-910. PubMed ID: 32293192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomes.
    Katikineni VS; Kant S; Gapud EJ; Antiochos B; Manno RL; Phillips M; Seo P; Geetha D
    Clin Rheumatol; 2019 Aug; 38(8):2195-2199. PubMed ID: 31037456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
    Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
    Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Recurrent Antineutrophil Cytoplasmic Antibody-Associated Vasculitis After Kidney Transplant With Rituximab: A Successful Case Report.
    Silva RM; Leal R; Marques MG; Rodrigues L; Santos L; Romaozinho C; Alves R; Figueiredo A
    Exp Clin Transplant; 2023 Feb; 21(2):171-174. PubMed ID: 36919725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
    Harris C; Marin J; Beaulieu MC
    BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.